Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children.
BACKGROUND
There are no studies on the use of cetirizine in children under the age of 6.


OBJECTIVE
We compared the efficacy and tolerability of cetirizine in patients with idiopathic chronic urticaria to the more widely used antihistamine, oxatomide.


METHODS
This double-blind study was performed on 62 patients (38 male and 24 female) with idiopathic chronic urticaria, recruited from four different medical centers of the national territory (Ancona, Cagliari, Catania, and Messina). The children's ages ranged from 2 to 6 years (mean 3.85). The patients were randomly assigned to two treatment groups: one group treated 31 children with cetirizine at a dosage of 5 mg q.d., and a second group treated 31 children for the same amount of time with oxatomide, at a dosage of 25 mg q.d. Sixty-two children began the treatment, but five did not finish the study (three in the cetirizine and two in the oxatomide group). Thus, the clinical study and the statistical evaluation were conducted on 57 children (28 cetirizine and 29 oxatomide). The Student's t test was used to compare severity of the illness and changes in the hematochemical tests.


RESULTS
Overall, the effectiveness of the two medications in treating erythema, papules, edema, and itching showed comparable therapeutic activity (P < 0.001). Neither medication produced significant side effects.


CONCLUSIONS
The results of the present study suggest that cetirizine may represent an effective and safe pharmacologic therapy for chronic urticaria in preschool children. There was no evidence for changes in hematochemical and urinary values, demonstrating the safety and the tolerability of the two antihistamines, even when given to young children.
La Rosa
M
M
Pediatric Department, University of Catania, Italy. mlarosa@mbox.unict.it
Leonardi
S
S
Marchese
G
G
Corrias
A
A
Barberio
G
G
Oggiano
N
N
Grimaldi
I
I
D018926:Anti-Allergic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D017332:Cetirizine / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002675:Child, Preschool; D002908:Chronic Disease; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006634:Histamine H1 Antagonists / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D014581:Urticaria / Q000188:drug therapy* / Q000209:etiology*
D018926:Anti-Allergic Agents; D006634:Histamine H1 Antagonists; D010879:Piperazines; C015408:oxatomide; D017332:Cetirizine